INmune Bio (INMB) Stock: Buy, Sell, or Hold?
INMB - INmune Bio Inc. Common stock
$2.22
-0.09 (-3.90%)
âŧ
5d:
-2.2%
30d:
+8.82%
90d:
+74.8%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When INMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: INMB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: INMB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: INMB is currently trading at $2.22, which is considered fair relative to its 30-day fair value range of $2.07 to $2.40.
Technical Outlook: Technically, INMB is in a strong uptrend. The price is currently testing key support at $2.21. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: INMB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (72th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $7.00 (+215.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INMB is in a strong uptrend. The price is currently testing key support at $2.21. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: INMB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (72th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $7.00 (+215.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.07 -
$2.40
Company Quality Score
32/100
(SELL)
Options IV Signal
72th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
35.4%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 72th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 215.3% below Wall St target ($7.00)
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.07 -
$2.40
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.44
(19.8%)
Support & Resistance Levels
Support Level
$2.21
Resistance Level
$2.60
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.53
Wall Street Target
$7.00
(+215.3%)
Revenue Growth (YoY)
257.1%
Share & Embed Analysis
Last updated: September 13, 2026 9:12 AM ET
Data refreshes hourly during market hours. Next update: 10:12 AM
Data refreshes hourly during market hours. Next update: 10:12 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
